The proportion of subjects who have a sustained virologic response (SVR; i.e., HCV RNA concentration below the lower limit of quantitation [<LLOQ; <25 IU/mL]) at 4 weeks after the last planned dose of treatment (SVR4) [ Time Frame: Up to 20 Weeks ] [ Designated as safety issue: No ]

The proportion of subjects who have an SVR at 12 weeks after the last planned dose of treatment (SVR12) [ Time Frame: Up to 28 weeks ] [ Designated as safety issue: No ]

The proportion of subjects who have an SVR at 44 weeks after the last planned dose of treatment (SVR24) [ Time Frame: Up to 40 weeks ] [ Designated as safety issue: No ]

The proportion of subjects who have virologic relapse [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]

The proportion of subjects who have virologic breakthrough [ Time Frame: Up to 16 weeks ] [ Designated as safety issue: No ]

The amino acid sequence of the nonstructural NS5A and NS5B proteins in subjects who have treatment failure [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]

The proportion of subjects who achieve SVR12 by HCV genotype 1 subtype (1a versus non-1a) [ Time Frame: Up to 28 weeks ] [ Designated as safety issue: No ]

The proportion of subjects who achieve SVR12 by IL-28B genotype (CC versus non-CC) [ Time Frame: Up to 28 weeks ] [ Designated as safety issue: No ]

Subjects must have genotype 1 CHC and evidence of HCV infection at least 6 months before screening

Subjects must be treatment-naïve and have not received prior treatment with any interferon, immunomodulatory agent, or DAA for HCV

Exclusion Criteria:

Evidence of cirrhosis

History or other clinical evidence of significant or unstable cardiac disease

Any other cause of significant liver disease in addition to hepatitis C

Creatinine clearance ≤50 mL/min using the Cockcroft-Gault equation at screening

Female subjects who are pregnant or nursing

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01842451